Login to Your Account



CFDA gives fast track status to Jiangsu Nhwa for epilepsy drug

By Shannon Ellis
Staff Writer

Tuesday, June 10, 2014
SHANGHAI – Jiangsu Nhwa Pharmaceutical Co. Ltd.'s DP-VPA, a modified valproic acid (VPA) treatment for epilepsy, has received fast track status from the CFDA. The drug was first licensed from D-Pharm Ltd., of Rehovot, Israel, in 2011 and holds promise for its targeted technology to be more potent and safer than other forms of VPA.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription